Content area
Abstract
The amyloid cascade hypothesis, which posits that the deposition of the amyloid-[beta] peptide in the brain is a central event in Alzheimer's disease pathology, has dominated research for the past twenty years. Several therapeutics that were purported to reduce amyloid-[beta] production or aggregation have failed in Phase III clinical testing, and many others are in various stages of development. Therefore, it is timely to review the science underpinning the amyloid cascade hypothesis, consider what type of clinical trials will constitute a valid test of this hypothesis and explore whether amyloid-[beta]-directed therapeutics will provide the medicines that are urgently needed by society for treating this devastating disease.